Table 5.
Characteristics and treatment modalities of atrial fibrillation in patients with cardiac amyloidosis
| Variable | Overall (n = 64) | AL‐CA (n = 20) | ATTR‐CA (n = 44) | P value |
|---|---|---|---|---|
| Age | 75 ± 9 | 67 ± 9 | 79 ± 5 | <0.001 |
| Male | 54 (84) | 13 (20) | 41 (64) | 0.004 |
| CHA2DS2‐VASc score | 3.7 (1.5) | 2.3 (1.0) | 4.4 (1.2) | <0.001 |
| EHRA symptom severity scale | ||||
| I | 20 (31) | 4 (20) | 16 (36) | 0.41 |
| IIa/b | 32 (50) | 12 (60) | 20 (46) | |
| III | 12 (19) | 4 (20) | 8 (18) | |
| IV | 0 (0) | 0 (0) | 0 (0) | |
| AF burden | ||||
| Permanent | 24 (38) | 5 (25) | 19 (43) | 0.14 |
| Persistent | 16 (25) | 4 (20) | 12 (27) | |
| Paroxysmal | 24 (38) | 11 (55) | 13 (54) | |
| Pharmacologic treatments | ||||
| Anticoagulation | 50 (78) | 12 (60) | 38 (86) | 0.03 |
| Vitamin K antagonist | 14 (22) | 6 (43) | 8 (57) | 0.29 |
| Direct oral anticoagulant | 36 (56) | 6 (30) | 30 (68) | 0.004 |
| Digitalis glycosides | 4 (6) | 2 (10) | 2 (5) | 0.37 |
| Beta‐blocker/Calcium channel blocker | 38 (59) | 10 (50) | 28 (64) | 0.41 |
| Amiodaron | 5 (8) | 1 (5) | 4 (9) | 0.50 |
| Non‐pharmacologic treatments | ||||
| Pacemaker | 9 (14) | 2 (10) | 7 (16) | 0.53 |
| Current cardioversion | 15 (23) | 3 (15) | 12 (27) | 0.28 |
| Catheter ablation | 8 (13) | 1 (5) | 7 (16) | 0.22 |
| Adverse clinical events | ||||
| Bleeding | 10 (16) | 4 (20) | 6 (14) | 0.71 |
| Stroke/TIA | 4 (6) | 2 (10) | 2 (5) | 0.37 |
AL, light‐chain amyloidosis; ATTR, transthyretin amyloidosis; CA, cardiac amyloidosis; EHRA, European Heart Rhythm Association; TIA, transient ischaemic attack.